As to early blood-based markers predicting responses to therapy, increased ALC [19, 23, 24], increased rate ALC to WBC [25], low neutrophil to lymphocyte ratio (NLR) [26], increased AEC [26], increased inducible co-stimulator [26, 27] on circulating CD4+ T cells, decreased MDSC [28, 29], increased Th12 cell inducibility [30], and melanoma markers on circulating cells (Melan-A, gp100, MAGE-3 and MIA) [31] have been reported. The gene discussed is MAGEA3; the disease is melanoma.